Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 20
1978 16
1979 37
1980 39
1981 34
1982 40
1983 39
1984 50
1985 53
1986 67
1987 48
1988 32
1989 29
1990 31
1991 31
1992 28
1993 33
1994 46
1995 48
1996 51
1997 60
1998 48
1999 65
2000 65
2001 68
2002 86
2003 72
2004 77
2005 75
2006 73
2007 76
2008 76
2009 60
2010 45
2011 61
2012 69
2013 53
2014 56
2015 52
2016 42
2017 36
2018 38
2019 37
2020 30
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

2,079 results
Results by year
Filters applied: . Clear all
Page 1
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Hüneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A. Burke CA, et al. N Engl J Med. 2020 Sep 10;383(11):1028-1039. doi: 10.1056/NEJMoa1916063. N Engl J Med. 2020. PMID: 32905675 Clinical Trial.
METHODS: We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in adults with familial adenomatous polyposis. ...Disease progression occurred in 18 of 56 patients (32%) in the eflornithine-sulindac
METHODS: We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in …
Studies on the metabolism and biological activity of the epimers of sulindac.
Brunell D, Sagher D, Kesaraju S, Brot N, Weissbach H. Brunell D, et al. Drug Metab Dispos. 2011 Jun;39(6):1014-21. doi: 10.1124/dmd.110.037663. Epub 2011 Mar 7. Drug Metab Dispos. 2011. PMID: 21383205 Free PMC article.
Previous results had indicated that the reduction of (S)-sulindac to sulindac sulfide, the active NSAID, was catalyzed by methionine sulfoxide reductase (Msr) A. ...(S)-Sulindac increases the activity of the P450 system better than (R)-sulindac, but bo …
Previous results had indicated that the reduction of (S)-sulindac to sulindac sulfide, the active NSAID, was catalyzed by meth …
Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.
Sung JW, Yun HY, Park S, Kim YJ, Yee J, Lee KE, Song B, Chung JE, Gwak HS. Sung JW, et al. Pharm Res. 2020 Jan 28;37(3):44. doi: 10.1007/s11095-020-2765-6. Pharm Res. 2020. PMID: 31993760
METHODS: Plasma samples were collected at 1.5, 4, and 10 h after first oral administration of sulindac. Plasma concentrations of sulindac and its active metabolite (sulindac sulfide) were determined, and pharmacokinetic analysis was performed with NONMEM 7.3. …
METHODS: Plasma samples were collected at 1.5, 4, and 10 h after first oral administration of sulindac. Plasma concentrations of s
Oxazole and thiazole analogs of sulindac for cancer prevention.
Mathew B, Hobrath JV, Connelly MC, Guy RK, Reynolds RC. Mathew B, et al. Future Med Chem. 2018 Apr 1;10(7):743-753. doi: 10.4155/fmc-2017-0182. Epub 2018 Apr 19. Future Med Chem. 2018. PMID: 29671617 Free PMC article.
Sulindac sulfide amide (SSA) is an amide-linked sulindac sulfide analog that showed in vivo antitumor activity in a human colon tumor xenograft model. Results/methodology: A new analog series with heterocyclic rings such as oxazole or thiazole at the C-2 position of
Sulindac sulfide amide (SSA) is an amide-linked sulindac sulfide analog that showed in vivo antitumor activity in a human colo
The efficacy and safety of sulindac for colorectal polyps: A protocol for systematic review and meta-analysis.
Long Q, Ao L, Li K, Li Y. Long Q, et al. Medicine (Baltimore). 2020 Oct 9;99(41):e22402. doi: 10.1097/MD.0000000000022402. Medicine (Baltimore). 2020. PMID: 33031275 Free PMC article.
BACKGROUND: Sulindac has been used for treating colorectal polyps widely. However, the efficacy and safety of sulindac for colorectal polyps are unclear. ...RESULTS: This study will summarize the present evidence by exploring the efficacy and safety of sulindac
BACKGROUND: Sulindac has been used for treating colorectal polyps widely. However, the efficacy and safety of sulindac for col …
Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.
Chandra S, Nymeyer AC, Rice PF, Gerner EW, Barton JK. Chandra S, et al. Cancer Prev Res (Phila). 2017 Aug;10(8):459-466. doi: 10.1158/1940-6207.CAPR-17-0038. Epub 2017 Jun 13. Cancer Prev Res (Phila). 2017. PMID: 28611038 Free PMC article.
Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, cycle repeated 5 times (sulindac-2); (iii) for 10 weeks ("on"), then no sulindac for 10 weeks ("off"; sulindac-10); and …
Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, c …
Clinical pharmacokinetics of sulindac. A dynamic old drug.
Davies NM, Watson MS. Davies NM, et al. Clin Pharmacokinet. 1997 Jun;32(6):437-59. doi: 10.2165/00003088-199732060-00002. Clin Pharmacokinet. 1997. PMID: 9195115 Review.
The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which has anti-inflammatory and analgesic properties and is irreversibly metabolised to sulindac sulphone which has been suggested to possess …
The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which ha …
Polymorphism versus devitrification mechanism: Low-wavenumber Raman investigations in sulindac.
Latreche M, Willart JF, Paccou L, Guinet Y, Hédoux A. Latreche M, et al. Int J Pharm. 2019 Aug 15;567:118476. doi: 10.1016/j.ijpharm.2019.118476. Epub 2019 Jun 27. Int J Pharm. 2019. PMID: 31255778
The polymorphism of sulindac was investigated by Raman investigations, mainly in the low-wavenumber region in order to analyze the influence of the amorphization method on recrystallization and crystalline form stability. ...This study has shown the enantiotropic relations …
The polymorphism of sulindac was investigated by Raman investigations, mainly in the low-wavenumber region in order to analyze the in …
Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2.
Aono Y, Horinaka M, Iizumi Y, Watanabe M, Taniguchi T, Yasuda S, Sakai T. Aono Y, et al. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1203-1210. doi: 10.1016/j.bbrc.2018.10.050. Epub 2018 Oct 14. Biochem Biophys Res Commun. 2018. PMID: 30327144
Sulindac sulfone is a metabolite of sulindac, a non-steroidal anti-inflammatory drug (NSAID), without anti-inflammatory ability. ...To date, the molecular targets of sulindac sulfone have not yet fully investigated. Therefore, in order to newly identify su
Sulindac sulfone is a metabolite of sulindac, a non-steroidal anti-inflammatory drug (NSAID), without anti-inflammatory abilit
Diverse amide analogs of sulindac for cancer treatment and prevention.
Mathew B, Hobrath JV, Connelly MC, Kiplin Guy R, Reynolds RC. Mathew B, et al. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4614-4621. doi: 10.1016/j.bmcl.2017.09.022. Epub 2017 Sep 13. Bioorg Med Chem Lett. 2017. PMID: 28935266 Free PMC article.
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activity. Sulindac sulfide amide (1) possessing greatly reduced COX-related inhibition relative to sulindac displayed in vivo antitumor activity that was comparab
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activity. Sulindac sulfide am
2,079 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback